Graypoint LLC Sells 3,305 Shares of Kenvue Inc. (NYSE:KVUE)

Graypoint LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 25.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 9,902 shares of the company’s stock after selling 3,305 shares during the period. Graypoint LLC’s holdings in Kenvue were worth $213,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. YHB Investment Advisors Inc. boosted its holdings in Kenvue by 398.7% in the 4th quarter. YHB Investment Advisors Inc. now owns 75,730 shares of the company’s stock worth $1,630,000 after buying an additional 60,543 shares during the period. Ingalls & Snyder LLC boosted its holdings in Kenvue by 0.7% in the 4th quarter. Ingalls & Snyder LLC now owns 425,091 shares of the company’s stock worth $9,152,000 after buying an additional 2,839 shares during the period. ORG Partners LLC boosted its holdings in Kenvue by 1,611.4% in the 4th quarter. ORG Partners LLC now owns 3,149 shares of the company’s stock worth $68,000 after buying an additional 2,965 shares during the period. Deroy & Devereaux Private Investment Counsel Inc. boosted its holdings in Kenvue by 19.9% in the 4th quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 16,966 shares of the company’s stock worth $365,000 after buying an additional 2,812 shares during the period. Finally, Birch Hill Investment Advisors LLC boosted its holdings in Kenvue by 50.1% in the 4th quarter. Birch Hill Investment Advisors LLC now owns 167,071 shares of the company’s stock worth $3,597,000 after buying an additional 55,766 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the subject of several research reports. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Royal Bank of Canada dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. Sanford C. Bernstein initiated coverage on shares of Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. Finally, UBS Group increased their price objective on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Price Performance

Kenvue stock opened at $19.13 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80. The company’s 50-day moving average is $19.88 and its 200 day moving average is $20.18.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s revenue for the quarter was down 2.7% on a year-over-year basis. Equities research analysts anticipate that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date of this dividend was Tuesday, February 13th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.